Gilead Sciences and Arcus Biosciences terminated additional trials of domvanalimab after a Phase 3 futility finding, according to disclosures. The partners ended STAR-121 in metastatic non-small cell lung cancer after an independent panel determined the domvanalimab comparison against Keytruda plus chemotherapy was futile. The decision also prompted Gilead to step back from the broader collaboration, while options tied to early-stage assets were set to end on a defined timeline. The filing indicated no new safety issues during regular check-ins, though the futility analysis did not include a safety review. For developers, the cull further highlights the volatility of immunotherapy combinations when head-to-head outcomes fail to show survival benefit in late-stage studies.